Bibliography: library/10665-331525-rus
The reference for library/10665-331525-rus (who-iris) and any references extracted from it. library · All references.
WHO. WHO operational handbook on tuberculosis: module 1: prevention: tuberculosis preventive treatment.
- Title
- WHO operational handbook on tuberculosis: module 1: prevention: tuberculosis preventive treatment
- Authors
- WHO
- Issued
- D:20210920
- Type
- document
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus - provenance: library
- read from
library/10665-331525-rus/manifest.jsonld(who-iris, sub-graph library) - library copy:
library/10665-331525-rus
Export these 119 references: BibTeX · CSL-JSON · RIS · Dublin Core XML · Dublin Core / BIBO JSON-LD
✍ + Add reference (standalone node)
119 shown
-
Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLOS Med. 2016;13(10):e1002152.
· extracted · source:references/10665-331525-rus.page-158.1.jsonHouben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLOS Med. 2016;13(10):e1002152.
- Issued
- 2016
- Type
- article-journal
- As printed
- Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLOS Med. 2016;13(10):e1002152.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.1 - provenance: extracted
- read from
references/10665-331525-rus.page-158.1.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Global tuberculosis report 2019. Geneva: World Health Organization; 2019 (http://www.who.int/tb/publications/global_report/en/, accessed 15 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.10.jsonGlobal tuberculosis report 2019. Geneva: World Health Organization; 2019 (http://www.who.int/tb/publications/global_report/en/, accessed 15 March 2020).
- Issued
- 2019
- Type
- document
- Accessed
- 15 March 2020
- As printed
- Global tuberculosis report 2019. Geneva: World Health Organization; 2019 (http://www.who.int/tb/publications/global_report/en/, accessed 15 March 2020).
Sources
- www.who.int/tb/publications/global_report/en/ (canonical)
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.10 - provenance: extracted
- read from
references/10665-331525-rus.page-158.10.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Priftin (rifapentine) tablets. Highlights of prescribing information. Maryland: U.S. Food and Drug Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf, accessed 18 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.100.jsonPriftin (rifapentine) tablets. Highlights of prescribing information. Maryland: U.S. Food and Drug Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf, accessed 18 March 2020).
- Issued
- 2016
- Type
- document
- Accessed
- 18 March 2020
- As printed
- Priftin (rifapentine) tablets. Highlights of prescribing information. Maryland: U.S. Food and Drug Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf, accessed 18 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.100 - provenance: extracted
- read from
references/10665-331525-rus.page-158.100.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Stagg HR, Zenner D, Harris RJ, Muñoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med. 2014;161(6):419–28.
· extracted · source:references/10665-331525-rus.page-158.101.jsonStagg HR, Zenner D, Harris RJ, Muñoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med. 2014;161(6):419–28.
- Issued
- 2014
- Type
- article-journal
- As printed
- Stagg HR, Zenner D, Harris RJ, Muñoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med. 2014;161(6):419–28.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.101 - provenance: extracted
- read from
references/10665-331525-rus.page-158.101.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Barbeau P, et al. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. Pharmacoepidemiol Drug Saf. 2018;27(6):557–66.
· extracted · source:references/10665-331525-rus.page-158.102.jsonPease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Barbeau P, et al. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. Pharmacoepidemiol Drug Saf. 2018;27(6):557–66.
- Issued
- 2018
- Type
- article-journal
- As printed
- Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Barbeau P, et al. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. Pharmacoepidemiol Drug Saf. 2018;27(6):557–66.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.102 - provenance: extracted
- read from
references/10665-331525-rus.page-158.102.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Pellagra and its prevention and control in major emergencies. Geneva: World Health Organization; 2000 (https://www.who.int/nutrition/publications/emergencies/WHO_NHD_00.10/en/, accessed 18 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.103.jsonPellagra and its prevention and control in major emergencies. Geneva: World Health Organization; 2000 (https://www.who.int/nutrition/publications/emergencies/WHO_NHD_00.10/en/, accessed 18 March 2020).
- Issued
- 2000
- Type
- document
- Accessed
- 18 March 2020
- As printed
- Pellagra and its prevention and control in major emergencies. Geneva: World Health Organization; 2000 (https://www.who.int/nutrition/publications/emergencies/WHO_NHD_00.10/en/, accessed 18 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.103 - provenance: extracted
- read from
references/10665-331525-rus.page-158.103.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Nursing guide for managing side effects to drug-resistant TB treatment. Berkeley: Curry international tuberculosis centre; 2018 (https://www.currytbcenter.ucsf.edu/products/view/nursing-guide-managing-side-effects-drug-resistant-tb-treatment, accessed 18 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.104.jsonNursing guide for managing side effects to drug-resistant TB treatment. Berkeley: Curry international tuberculosis centre; 2018 (https://www.currytbcenter.ucsf.edu/products/view/nursing-guide-managing-side-effects-drug-resistant-tb-treatment, accessed 18 March 2020).
- Issued
- 2018
- Type
- document
- Accessed
- 18 March 2020
- As printed
- Nursing guide for managing side effects to drug-resistant TB treatment. Berkeley: Curry international tuberculosis centre; 2018 (https://www.currytbcenter.ucsf.edu/products/view/nursing-guide-managing-side-effects-drug-resistant-tb-treatment, accessed 18 March 2020).
Sources
- www.currytbcenter.ucsf.edu/products/view/nursing-guide-managing-side-effects-drug-resistant-tb-treatment (canonical)
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.104 - provenance: extracted
- read from
references/10665-331525-rus.page-158.104.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
William JB, Keith G, Charles P. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001;40:327–41.
· extracted · source:references/10665-331525-rus.page-158.105.jsonWilliam JB, Keith G, Charles P. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001;40:327–41.
- Issued
- 2001
- Type
- article-journal
- As printed
- William JB, Keith G, Charles P. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001;40:327–41.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.105 - provenance: extracted
- read from
references/10665-331525-rus.page-158.105.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
HIV drug interaction checker. University of Liverpool [веб-сайт] (https://www.hiv-druginteractions.org/checker, accessed 18 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.106.jsonHIV drug interaction checker. University of Liverpool [веб-сайт] (https://www.hiv-druginteractions.org/checker, accessed 18 March 2020).
- Type
- document
- Accessed
- 18 March 2020
- As printed
- HIV drug interaction checker. University of Liverpool [веб-сайт] (https://www.hiv-druginteractions.org/checker, accessed 18 March 2020).
Sources
- www.hiv-druginteractions.org/checker (canonical)
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.106 - provenance: extracted
- read from
references/10665-331525-rus.page-158.106.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Dolutegravir (DTG) and the fixed dose combination (FDC) of tenofovir/lamivudine/dolutegravir (TLD). HIV/AIDS. World Health Organization [веб-сайт]; 2018 (https://www.who.int/hiv/topics/treatment/dtg-tld-briefing-web/en/ accessed 18 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.107.jsonDolutegravir (DTG) and the fixed dose combination (FDC) of tenofovir/lamivudine/dolutegravir (TLD). HIV/AIDS. World Health Organization [веб-сайт]; 2018 (https://www.who.int/hiv/topics/treatment/dtg-tld-briefing-web/en/ accessed 18 March 2020).
- Issued
- 2018
- Type
- document
- Accessed
- 18 March 2020
- As printed
- Dolutegravir (DTG) and the fixed dose combination (FDC) of tenofovir/lamivudine/dolutegravir (TLD). HIV/AIDS. World Health Organization [веб-сайт]; 2018 (https://www.who.int/hiv/topics/treatment/dtg-tld-briefing-web/en/ accessed 18 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.107 - provenance: extracted
- read from
references/10665-331525-rus.page-158.107.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, et al. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial. Clin Infect Dis. 2020; 70(4):549–56.
· extracted · source:references/10665-331525-rus.page-158.108.jsonDooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, et al. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial. Clin Infect Dis. 2020; 70(4):549–56.
- Issued
- 2020
- Type
- article-journal
- As printed
- Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, et al. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial. Clin Infect Dis. 2020; 70(4):549–56.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.108 - provenance: extracted
- read from
references/10665-331525-rus.page-158.108.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, et al. Efavirenz pharmacokinetics and pharmacodynamics in hiv-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis. 2015;61(8):1322–7.
· extracted · source:references/10665-331525-rus.page-158.109.jsonPodany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, et al. Efavirenz pharmacokinetics and pharmacodynamics in hiv-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis. 2015;61(8):1322–7.
- Issued
- 2015
- Type
- article-journal
- As printed
- Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, et al. Efavirenz pharmacokinetics and pharmacodynamics in hiv-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis. 2015;61(8):1322–7.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.109 - provenance: extracted
- read from
references/10665-331525-rus.page-158.109.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Политическая декларация заседания высокого уровня Генеральной Ассамблеи по борьбе с туберкулезом. Семьдесят третья сессия Генеральной ассамблеи ООН; 2018 https://undocs.org/ru/A/RES/73/3, по состоянию на 31 марта 2021 г.).
· extracted · link · source:references/10665-331525-rus.page-158.11.jsonПолитическая декларация заседания высокого уровня Генеральной Ассамблеи по борьбе с туберкулезом. Семьдесят третья сессия Генеральной ассамблеи ООН; 2018 https://undocs.org/ru/A/RES/73/3, по состоянию на 31 марта 2021 г.).
- Issued
- 2021
- Type
- document
- As printed
- Политическая декларация заседания высокого уровня Генеральной Ассамблеи по борьбе с туберкулезом. Семьдесят третья сессия Генеральной ассамблеи ООН; 2018 https://undocs.org/ru/A/RES/73/3, по состоянию на 31 марта 2021 г.).
Sources
- undocs.org/ru/A/RES/73/3 (canonical)
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.11 - provenance: extracted
- read from
references/10665-331525-rus.page-158.11.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JAL, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2014;69(4):1079–85.
· extracted · source:references/10665-331525-rus.page-158.110.jsonWeiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JAL, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2014;69(4):1079–85.
- Issued
- 2014
- Type
- article-journal
- As printed
- Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JAL, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2014;69(4):1079–85.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.110 - provenance: extracted
- read from
references/10665-331525-rus.page-158.110.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12(2):111–8.
· extracted · source:references/10665-331525-rus.page-158.111.jsonvan Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12(2):111–8.
- Issued
- 2012
- Type
- article-journal
- As printed
- van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12(2):111–8.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.111 - provenance: extracted
- read from
references/10665-331525-rus.page-158.111.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Dooley KE, Churchyard G, Savic RM, Gupta A, Marzinke M, Zhang N, et al. Safety & PK of weekly rifapentine/isoniazid (3HP) in adults with HIV on dolutegravir. Abstract 80. TB: From contact to cure and beyond. Conference on Retroviruses and Opportunistic Infections. March 4–7, 2019. Seattle, Washington (https://www.croiconference.org/abstract/safety-pk-weekly-rifapentineisoniazid-3hp-adults-hiv-dolutegravir/, accessed 18 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.112.jsonDooley KE, Churchyard G, Savic RM, Gupta A, Marzinke M, Zhang N, et al. Safety & PK of weekly rifapentine/isoniazid (3HP) in adults with HIV on dolutegravir. Abstract 80. TB: From contact to cure and beyond. Conference on Retroviruses and Opportunistic Infections. March 4–7, 2019. Seattle, Washington (https://www.croiconference.org/abstract/safety-pk-weekly-rifapentineisoniazid-3hp-adults-hiv-dolutegravir/, accessed 18 March 2020).
- Issued
- 2019
- Type
- document
- Accessed
- 18 March 2020
- As printed
- Dooley KE, Churchyard G, Savic RM, Gupta A, Marzinke M, Zhang N, et al. Safety & PK of weekly rifapentine/isoniazid (3HP) in adults with HIV on dolutegravir. Abstract 80. TB: From contact to cure and beyond. Conference on Retroviruses and Opportunistic Infections. March 4–7, 2019. Seattle, Washington (https://www.croiconference.org/abstract/safety-pk-weekly-rifapentineisoniazid-3hp-adults-hiv-dolutegravir/, accessed 18 March 2020).
Sources
- www.croiconference.org/abstract/safety-pk-weekly-rifapentineisoniazid-3hp-adults-hiv-dolutegravir/ (canonical)
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.112 - provenance: extracted
- read from
references/10665-331525-rus.page-158.112.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
López-Cortés LF, Ruiz-Valderas R, Viciana P, Alarcón-González A, Gómez-Mateos J, León-Jimenez E, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002;41(9):681–90.
· extracted · source:references/10665-331525-rus.page-158.113.jsonLópez-Cortés LF, Ruiz-Valderas R, Viciana P, Alarcón-González A, Gómez-Mateos J, León-Jimenez E, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002;41(9):681–90.
- Issued
- 2002
- Type
- article-journal
- As printed
- López-Cortés LF, Ruiz-Valderas R, Viciana P, Alarcón-González A, Gómez-Mateos J, León-Jimenez E, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002;41(9):681–90.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.113 - provenance: extracted
- read from
references/10665-331525-rus.page-158.113.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, et al. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013;57(4):586–93.
· extracted · source:references/10665-331525-rus.page-158.114.jsonLuetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, et al. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013;57(4):586–93.
- Issued
- 2013
- Type
- article-journal
- As printed
- Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, et al. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013;57(4):586–93.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.114 - provenance: extracted
- read from
references/10665-331525-rus.page-158.114.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Faren C, Dourumian S, Cantalloube C, Perrin L, Esposito V, Cierien-Puiseux I, et al. Rifapentine once-weekly dosing effect on efavirenz, emtricitabine and tenofovir PKs. Abstract 493. Clinical Pharmacology of TB and HCV Coinfection. Conference on Retroviruses and Opportunistic Infections. March 4–7, 2019. Seattle, Washington (http://www.croiconference.org/sites/default/files/abstracts/493.pdf, accessed 18 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.115.jsonFaren C, Dourumian S, Cantalloube C, Perrin L, Esposito V, Cierien-Puiseux I, et al. Rifapentine once-weekly dosing effect on efavirenz, emtricitabine and tenofovir PKs. Abstract 493. Clinical Pharmacology of TB and HCV Coinfection. Conference on Retroviruses and Opportunistic Infections. March 4–7, 2019. Seattle, Washington (http://www.croiconference.org/sites/default/files/abstracts/493.pdf, accessed 18 March 2020).
- Issued
- 2019
- Type
- document
- Accessed
- 18 March 2020
- As printed
- Faren C, Dourumian S, Cantalloube C, Perrin L, Esposito V, Cierien-Puiseux I, et al. Rifapentine once-weekly dosing effect on efavirenz, emtricitabine and tenofovir PKs. Abstract 493. Clinical Pharmacology of TB and HCV Coinfection. Conference on Retroviruses and Opportunistic Infections. March 4–7, 2019. Seattle, Washington (http://www.croiconference.org/sites/default/files/abstracts/493.pdf, accessed 18 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.115 - provenance: extracted
- read from
references/10665-331525-rus.page-158.115.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Medication Guide. Descovy® (emtricitabine and tenofovir alafenamide tablets). Foster City: Gilead Sciences (https://www.gilead.com/-/media/files/pdfs/medicines/hiv/descovy/descovy_patient_pi.pdf, accessed 18 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.116.jsonMedication Guide. Descovy® (emtricitabine and tenofovir alafenamide tablets). Foster City: Gilead Sciences (https://www.gilead.com/-/media/files/pdfs/medicines/hiv/descovy/descovy_patient_pi.pdf, accessed 18 March 2020).
- Type
- document
- Accessed
- 18 March 2020
- As printed
- Medication Guide. Descovy® (emtricitabine and tenofovir alafenamide tablets). Foster City: Gilead Sciences (https://www.gilead.com/-/media/files/pdfs/medicines/hiv/descovy/descovy_patient_pi.pdf, accessed 18 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.116 - provenance: extracted
- read from
references/10665-331525-rus.page-158.116.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Cerrone M, Alfarisi O, Neary M, Marzinke MA, Parsons TL, Owen A, et al. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. J Antimicrob Chemother. 2019;74(6):1670–8.
· extracted · source:references/10665-331525-rus.page-158.117.jsonCerrone M, Alfarisi O, Neary M, Marzinke MA, Parsons TL, Owen A, et al. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. J Antimicrob Chemother. 2019;74(6):1670–8.
- Issued
- 2019
- Type
- article-journal
- As printed
- Cerrone M, Alfarisi O, Neary M, Marzinke MA, Parsons TL, Owen A, et al. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. J Antimicrob Chemother. 2019;74(6):1670–8.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.117 - provenance: extracted
- read from
references/10665-331525-rus.page-158.117.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé J-B, et al. Effect of isoniazid preventive therapy Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080–9.
· extracted · source:references/10665-331525-rus.page-158.118.jsonBadje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé J-B, et al. Effect of isoniazid preventive therapy Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080–9.
- Issued
- 2017
- Type
- article-journal
- As printed
- Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé J-B, et al. Effect of isoniazid preventive therapy Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080–9.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.118 - provenance: extracted
- read from
references/10665-331525-rus.page-158.118.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
WHO consolidated guidelines on tuberculosis: Module 1: Tuberculosis preventive treatment. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/bitstream/handle/10665/331170/9789240001503-eng.pdf, accessed 15 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.12.json· held:library/10665-331170WHO consolidated guidelines on tuberculosis: Module 1: Tuberculosis preventive treatment. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/bitstream/handle/10665/331170/9789240001503-eng.pdf, accessed 15 March 2020).
- Issued
- 2020
- Type
- document
- Accessed
- 15 March 2020
- As printed
- WHO consolidated guidelines on tuberculosis: Module 1: Tuberculosis preventive treatment. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/bitstream/handle/10665/331170/9789240001503-eng.pdf, accessed 15 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.12 - provenance: extracted
- read from
references/10665-331525-rus.page-158.12.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md - library copy:
library/10665-331170
-
Monitoring the building blocks of health systems: a handbook of indicators and their measurement strategies. Geneva: World Health Organization; 2010 (https://www.who.int/healthinfo/systems/WHO_MBHSS_2010_full_web.pdf, accessed 15 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.13.jsonMonitoring the building blocks of health systems: a handbook of indicators and their measurement strategies. Geneva: World Health Organization; 2010 (https://www.who.int/healthinfo/systems/WHO_MBHSS_2010_full_web.pdf, accessed 15 March 2020).
- Issued
- 2010
- Type
- document
- Accessed
- 15 March 2020
- As printed
- Monitoring the building blocks of health systems: a handbook of indicators and their measurement strategies. Geneva: World Health Organization; 2010 (https://www.who.int/healthinfo/systems/WHO_MBHSS_2010_full_web.pdf, accessed 15 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.13 - provenance: extracted
- read from
references/10665-331525-rus.page-158.13.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269–78.
· extracted · source:references/10665-331525-rus.page-158.14.jsonAlsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269–78.
- Issued
- 2016
- Type
- article-journal
- As printed
- Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269–78.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.14 - provenance: extracted
- read from
references/10665-331525-rus.page-158.14.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Lönnroth K, Migliori GB, Abubakar I, D’Ambrosio L, Vries G de, Diel R, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45(4):928–52.
· extracted · source:references/10665-331525-rus.page-158.15.jsonLönnroth K, Migliori GB, Abubakar I, D’Ambrosio L, Vries G de, Diel R, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45(4):928–52.
- Issued
- 2015
- Type
- article-journal
- As printed
- Lönnroth K, Migliori GB, Abubakar I, D’Ambrosio L, Vries G de, Diel R, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45(4):928–52.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.15 - provenance: extracted
- read from
references/10665-331525-rus.page-158.15.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Ford N, Matteelli A, Shubber Z, Hermans S, Meintjes G, Grinsztejn B, et al. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. J Int AIDS Soc. 2016;19(1):20714.
· extracted · source:references/10665-331525-rus.page-158.16.jsonFord N, Matteelli A, Shubber Z, Hermans S, Meintjes G, Grinsztejn B, et al. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. J Int AIDS Soc. 2016;19(1):20714.
- Issued
- 2016
- Type
- article-journal
- As printed
- Ford N, Matteelli A, Shubber Z, Hermans S, Meintjes G, Grinsztejn B, et al. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. J Int AIDS Soc. 2016;19(1):20714.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.16 - provenance: extracted
- read from
references/10665-331525-rus.page-158.16.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé J-B, et al. Effect of isoniazid preventive therapy Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080–9.
· extracted · source:references/10665-331525-rus.page-158.17.jsonBadje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé J-B, et al. Effect of isoniazid preventive therapy Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080–9.
- Issued
- 2017
- Type
- article-journal
- As printed
- Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé J-B, et al. Effect of isoniazid preventive therapy Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080–9.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.17 - provenance: extracted
- read from
references/10665-331525-rus.page-158.17.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Guidelines for intensified tuberculosis case-finding and isoniazid preventative therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization; 2011 (https://apps.who.int/iris/bitstream/handle/10665/44472/9789241500708_eng.pdf, accessed 15 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.18.jsonGuidelines for intensified tuberculosis case-finding and isoniazid preventative therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization; 2011 (https://apps.who.int/iris/bitstream/handle/10665/44472/9789241500708_eng.pdf, accessed 15 March 2020).
- Issued
- 2011
- Type
- document
- Accessed
- 15 March 2020
- As printed
- Guidelines for intensified tuberculosis case-finding and isoniazid preventative therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization; 2011 (https://apps.who.int/iris/bitstream/handle/10665/44472/9789241500708_eng.pdf, accessed 15 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.18 - provenance: extracted
- read from
references/10665-331525-rus.page-158.18.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Bruins WS, Leth F van. Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review. Infect Dis. 2017;49(3):161–9.
· extracted · source:references/10665-331525-rus.page-158.19.jsonBruins WS, Leth F van. Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review. Infect Dis. 2017;49(3):161–9.
- Issued
- 2017
- Type
- article-journal
- As printed
- Bruins WS, Leth F van. Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review. Infect Dis. 2017;49(3):161–9.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.19 - provenance: extracted
- read from
references/10665-331525-rus.page-158.19.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54(3):1900655.
· extracted · source:references/10665-331525-rus.page-158.2.jsonCohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54(3):1900655.
- Issued
- 2019
- Type
- article-journal
- As printed
- Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54(3):1900655.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.2 - provenance: extracted
- read from
references/10665-331525-rus.page-158.2.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Cotton M, Schaaf HS, Lottering G, Weber HL, Coetzee J, Nachman S. Tuberculosis exposure in HIV-exposed infants in a high-prevalence setting. Int J Tuberc Lung Dis. 2008;12(2):225–7.
· extracted · source:references/10665-331525-rus.page-158.20.jsonCotton M, Schaaf HS, Lottering G, Weber HL, Coetzee J, Nachman S. Tuberculosis exposure in HIV-exposed infants in a high-prevalence setting. Int J Tuberc Lung Dis. 2008;12(2):225–7.
- Issued
- 2008
- Type
- article-journal
- As printed
- Cotton M, Schaaf HS, Lottering G, Weber HL, Coetzee J, Nachman S. Tuberculosis exposure in HIV-exposed infants in a high-prevalence setting. Int J Tuberc Lung Dis. 2008;12(2):225–7.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.20 - provenance: extracted
- read from
references/10665-331525-rus.page-158.20.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Cranmer LM, Kanyugo M, Jonnalagadda SR, Lohman-Payne B, Sorensen B, Maleche Obimbo E, et al. High prevalence of tuberculosis infection in HIV-1 exposed Kenyan infants: Pediatr Infect Dis J. 2014;33(4):401–6.
· extracted · source:references/10665-331525-rus.page-158.21.jsonCranmer LM, Kanyugo M, Jonnalagadda SR, Lohman-Payne B, Sorensen B, Maleche Obimbo E, et al. High prevalence of tuberculosis infection in HIV-1 exposed Kenyan infants: Pediatr Infect Dis J. 2014;33(4):401–6.
- Issued
- 2014
- Type
- article-journal
- As printed
- Cranmer LM, Kanyugo M, Jonnalagadda SR, Lohman-Payne B, Sorensen B, Maleche Obimbo E, et al. High prevalence of tuberculosis infection in HIV-1 exposed Kenyan infants: Pediatr Infect Dis J. 2014;33(4):401–6.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.21 - provenance: extracted
- read from
references/10665-331525-rus.page-158.21.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Kali PBN, Gray GE, Violari A, Chaisson RE, McIntyre JA, Martinson NA. Combining PMTCT with active case finding for tuberculosis. J Acquir Immune Defic Syndr 1999. 2006;42(3):379–81.
· extracted · source:references/10665-331525-rus.page-158.22.jsonKali PBN, Gray GE, Violari A, Chaisson RE, McIntyre JA, Martinson NA. Combining PMTCT with active case finding for tuberculosis. J Acquir Immune Defic Syndr 1999. 2006;42(3):379–81.
- Issued
- 2006
- Type
- article-journal
- As printed
- Kali PBN, Gray GE, Violari A, Chaisson RE, McIntyre JA, Martinson NA. Combining PMTCT with active case finding for tuberculosis. J Acquir Immune Defic Syndr 1999. 2006;42(3):379–81.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.22 - provenance: extracted
- read from
references/10665-331525-rus.page-158.22.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Sterling TR, Alwood K, Gachuhi R, Coggin W, Blazes D, Bishai WR, et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS. 1999;13(14):1899–904.
· extracted · source:references/10665-331525-rus.page-158.23.jsonSterling TR, Alwood K, Gachuhi R, Coggin W, Blazes D, Bishai WR, et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS. 1999;13(14):1899–904.
- Issued
- 1999
- Type
- article-journal
- As printed
- Sterling TR, Alwood K, Gachuhi R, Coggin W, Blazes D, Bishai WR, et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS. 1999;13(14):1899–904.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.23 - provenance: extracted
- read from
references/10665-331525-rus.page-158.23.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999;353(9167):1843–7.
· extracted · source:references/10665-331525-rus.page-158.24.jsonVernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999;353(9167):1843–7.
- Issued
- 1999
- Type
- article-journal
- As printed
- Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999;353(9167):1843–7.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.24 - provenance: extracted
- read from
references/10665-331525-rus.page-158.24.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med. 1993;328(16):1137–44.
· extracted · source:references/10665-331525-rus.page-158.25.jsonSmall PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med. 1993;328(16):1137–44.
- Issued
- 1993
- Type
- article-journal
- As printed
- Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med. 1993;328(16):1137–44.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.25 - provenance: extracted
- read from
references/10665-331525-rus.page-158.25.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Crampin AC, Mwaungulu JN, Mwaungulu FD, Mwafulirwa DT, Munthali K, Floyd S, et al. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS. 2010;24(3):417–26.
· extracted · source:references/10665-331525-rus.page-158.26.jsonCrampin AC, Mwaungulu JN, Mwaungulu FD, Mwafulirwa DT, Munthali K, Floyd S, et al. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS. 2010;24(3):417–26.
- Issued
- 2010
- Type
- article-journal
- As printed
- Crampin AC, Mwaungulu JN, Mwaungulu FD, Mwafulirwa DT, Munthali K, Floyd S, et al. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS. 2010;24(3):417–26.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.26 - provenance: extracted
- read from
references/10665-331525-rus.page-158.26.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Narayanan S, Swaminathan S, Supply P, Shanmugam S, Narendran G, Hari L, et al. Impact of HIV infection on the recurrence of tuberculosis in South India. J Infect Dis. 2010;201(5):691–703.
· extracted · source:references/10665-331525-rus.page-158.27.jsonNarayanan S, Swaminathan S, Supply P, Shanmugam S, Narendran G, Hari L, et al. Impact of HIV infection on the recurrence of tuberculosis in South India. J Infect Dis. 2010;201(5):691–703.
- Issued
- 2010
- Type
- article-journal
- As printed
- Narayanan S, Swaminathan S, Supply P, Shanmugam S, Narendran G, Hari L, et al. Impact of HIV infection on the recurrence of tuberculosis in South India. J Infect Dis. 2010;201(5):691–703.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.27 - provenance: extracted
- read from
references/10665-331525-rus.page-158.27.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Chaisson RE, Churchyard GJ. Recurrent tuberculosis – relapse, reinfection and HIV. J Infect Dis. 2010;201(5):653–5.
· extracted · source:references/10665-331525-rus.page-158.28.jsonChaisson RE, Churchyard GJ. Recurrent tuberculosis – relapse, reinfection and HIV. J Infect Dis. 2010;201(5):653–5.
- Issued
- 2010
- Type
- article-journal
- As printed
- Chaisson RE, Churchyard GJ. Recurrent tuberculosis – relapse, reinfection and HIV. J Infect Dis. 2010;201(5):653–5.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.28 - provenance: extracted
- read from
references/10665-331525-rus.page-158.28.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Naidoo K, Dookie N. Insights into recurrent tuberculosis: relapse versus reinfection and related risk factors. London: IntechOpen; 2018 (https://www.intechopen.com/books/tuberculosis/insights-into-recurrent-tuberculosis-relapse-versus-reinfection-and-related-risk-factors, accessed 15 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.29.jsonNaidoo K, Dookie N. Insights into recurrent tuberculosis: relapse versus reinfection and related risk factors. London: IntechOpen; 2018 (https://www.intechopen.com/books/tuberculosis/insights-into-recurrent-tuberculosis-relapse-versus-reinfection-and-related-risk-factors, accessed 15 March 2020).
- Issued
- 2018
- Type
- document
- Accessed
- 15 March 2020
- As printed
- Naidoo K, Dookie N. Insights into recurrent tuberculosis: relapse versus reinfection and related risk factors. London: IntechOpen; 2018 (https://www.intechopen.com/books/tuberculosis/insights-into-recurrent-tuberculosis-relapse-versus-reinfection-and-related-risk-factors, accessed 15 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.29 - provenance: extracted
- read from
references/10665-331525-rus.page-158.29.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127–35.
· extracted · source:references/10665-331525-rus.page-158.3.jsonGetahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127–35.
- Issued
- 2015
- Type
- article-journal
- As printed
- Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127–35.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.3 - provenance: extracted
- read from
references/10665-331525-rus.page-158.3.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Systematic screening for active tuberculosis: principles and recommendations. Geneva: World Health Organization; 2013 (https://www.who.int/tb/tbscreening/en/, accessed 15 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.30.jsonSystematic screening for active tuberculosis: principles and recommendations. Geneva: World Health Organization; 2013 (https://www.who.int/tb/tbscreening/en/, accessed 15 March 2020).
- Issued
- 2013
- Type
- document
- Accessed
- 15 March 2020
- As printed
- Systematic screening for active tuberculosis: principles and recommendations. Geneva: World Health Organization; 2013 (https://www.who.int/tb/tbscreening/en/, accessed 15 March 2020).
Sources
- www.who.int/tb/tbscreening/en/ (canonical)
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.30 - provenance: extracted
- read from
references/10665-331525-rus.page-158.30.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middle-income countries. Geneva: World Health Organization; 2012 (https://www.who.int/tb/publications/2012/contact_investigation2012/en/, accessed 15 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.31.jsonRecommendations for investigating contacts of persons with infectious tuberculosis in low- and middle-income countries. Geneva: World Health Organization; 2012 (https://www.who.int/tb/publications/2012/contact_investigation2012/en/, accessed 15 March 2020).
- Issued
- 2012
- Type
- document
- Accessed
- 15 March 2020
- As printed
- Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middle-income countries. Geneva: World Health Organization; 2012 (https://www.who.int/tb/publications/2012/contact_investigation2012/en/, accessed 15 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.31 - provenance: extracted
- read from
references/10665-331525-rus.page-158.31.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
WHO Guidelines on tuberculosis infection prevention and control, 2019 update Geneva: World Health Organization; 2019 (https://www.who.int/tb/publications/2019/guidelines-tuberculosis-infection-prevention-2019/en/, accessed 15 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.32.jsonWHO Guidelines on tuberculosis infection prevention and control, 2019 update Geneva: World Health Organization; 2019 (https://www.who.int/tb/publications/2019/guidelines-tuberculosis-infection-prevention-2019/en/, accessed 15 March 2020).
- Issued
- 2019
- Type
- document
- Accessed
- 15 March 2020
- As printed
- WHO Guidelines on tuberculosis infection prevention and control, 2019 update Geneva: World Health Organization; 2019 (https://www.who.int/tb/publications/2019/guidelines-tuberculosis-infection-prevention-2019/en/, accessed 15 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.32 - provenance: extracted
- read from
references/10665-331525-rus.page-158.32.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Политика ВОЗ в отношении сотрудничества в области ТБ/ВИЧ. Руководящие принципы для национальных программ и других заинтересованных сторон. Женева: Всемирная организация здравоохранения; 2012 (http://whqlibdoc.who.int/publications/2012/9789241503006_eng_Annexes.pdf, по состоянию на 31 марта 2021 г.).
· extracted · link · source:references/10665-331525-rus.page-158.33.jsonПолитика ВОЗ в отношении сотрудничества в области ТБ/ВИЧ. Руководящие принципы для национальных программ и других заинтересованных сторон. Женева: Всемирная организация здравоохранения; 2012 (http://whqlibdoc.who.int/publications/2012/9789241503006_eng_Annexes.pdf, по состоянию на 31 марта 2021 г.).
- Issued
- 2021
- Type
- document
- As printed
- Политика ВОЗ в отношении сотрудничества в области ТБ/ВИЧ. Руководящие принципы для национальных программ и других заинтересованных сторон. Женева: Всемирная организация здравоохранения; 2012 (http://whqlibdoc.who.int/publications/2012/9789241503006_eng_Annexes.pdf, по состоянию на 31 марта 2021 г.).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.33 - provenance: extracted
- read from
references/10665-331525-rus.page-158.33.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2013;41(1):140–156.
· extracted · source:references/10665-331525-rus.page-158.34.jsonFox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2013;41(1):140–156.
- Issued
- 2013
- Type
- article-journal
- As printed
- Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2013;41(1):140–156.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.34 - provenance: extracted
- read from
references/10665-331525-rus.page-158.34.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Morrison J, Pai M, Hopewell PC. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8(6):359–368.
· extracted · source:references/10665-331525-rus.page-158.35.jsonMorrison J, Pai M, Hopewell PC. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8(6):359–368.
- Issued
- 2008
- Type
- article-journal
- As printed
- Morrison J, Pai M, Hopewell PC. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8(6):359–368.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.35 - provenance: extracted
- read from
references/10665-331525-rus.page-158.35.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Gupta A, Swindells S, Kim S, Hughes MD, Naini L, Wu X, et al. Feasibility of identifying household contacts of rifampin-and multidrug-resistant tuberculosis cases at high risk of progression to tuberculosis disease. Clin Infect Dis. 2020; 70(3):425–35.
· extracted · source:references/10665-331525-rus.page-158.36.jsonGupta A, Swindells S, Kim S, Hughes MD, Naini L, Wu X, et al. Feasibility of identifying household contacts of rifampin-and multidrug-resistant tuberculosis cases at high risk of progression to tuberculosis disease. Clin Infect Dis. 2020; 70(3):425–35.
- Issued
- 2020
- Type
- article-journal
- As printed
- Gupta A, Swindells S, Kim S, Hughes MD, Naini L, Wu X, et al. Feasibility of identifying household contacts of rifampin-and multidrug-resistant tuberculosis cases at high risk of progression to tuberculosis disease. Clin Infect Dis. 2020; 70(3):425–35.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.36 - provenance: extracted
- read from
references/10665-331525-rus.page-158.36.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Lung T, Marks GB, Nhung NV, Anh NT, Hoa NLP, Anh LTN, et al. Household contact investigation for the detection of tuberculosis in Vietnam: economic evaluation of a cluster-randomised trial. Lancet Glob Health. 2019;7(3):e376–84.
· extracted · source:references/10665-331525-rus.page-158.37.jsonLung T, Marks GB, Nhung NV, Anh NT, Hoa NLP, Anh LTN, et al. Household contact investigation for the detection of tuberculosis in Vietnam: economic evaluation of a cluster-randomised trial. Lancet Glob Health. 2019;7(3):e376–84.
- Issued
- 2019
- Type
- article-journal
- As printed
- Lung T, Marks GB, Nhung NV, Anh NT, Hoa NLP, Anh LTN, et al. Household contact investigation for the detection of tuberculosis in Vietnam: economic evaluation of a cluster-randomised trial. Lancet Glob Health. 2019;7(3):e376–84.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.37 - provenance: extracted
- read from
references/10665-331525-rus.page-158.37.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Sulis G, Combary A, Getahun H, Gnanou S, Giorgetti PF, Konseimb A, et al. Implementation of tuberculosis prevention for exposed children, Burkina Faso. Bull World Health Organ. 2018;(96):386–92.
· extracted · source:references/10665-331525-rus.page-158.38.jsonSulis G, Combary A, Getahun H, Gnanou S, Giorgetti PF, Konseimb A, et al. Implementation of tuberculosis prevention for exposed children, Burkina Faso. Bull World Health Organ. 2018;(96):386–92.
- Issued
- 2018
- Type
- document
- As printed
- Sulis G, Combary A, Getahun H, Gnanou S, Giorgetti PF, Konseimb A, et al. Implementation of tuberculosis prevention for exposed children, Burkina Faso. Bull World Health Organ. 2018;(96):386–92.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.38 - provenance: extracted
- read from
references/10665-331525-rus.page-158.38.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Prevent TB: a mobile app to support programmatic management of LTBI. Geneva: World Health Organization; 2020 (https://www.who.int/tb/prevent-tb-digital-platform/en/, по состоянию на 31 марта 2021 г.).
· extracted · link · source:references/10665-331525-rus.page-158.39.jsonPrevent TB: a mobile app to support programmatic management of LTBI. Geneva: World Health Organization; 2020 (https://www.who.int/tb/prevent-tb-digital-platform/en/, по состоянию на 31 марта 2021 г.).
- Issued
- 2021
- Type
- document
- As printed
- Prevent TB: a mobile app to support programmatic management of LTBI. Geneva: World Health Organization; 2020 (https://www.who.int/tb/prevent-tb-digital-platform/en/, по состоянию на 31 марта 2021 г.).
Sources
- www.who.int/tb/prevent-tb-digital-platform/en/ (canonical)
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.39 - provenance: extracted
- read from
references/10665-331525-rus.page-158.39.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974;99(2):131–8.
· extracted · source:references/10665-331525-rus.page-158.4.jsonComstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974;99(2):131–8.
- Issued
- 1974
- Type
- article-journal
- As printed
- Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974;99(2):131–8.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.4 - provenance: extracted
- read from
references/10665-331525-rus.page-158.4.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Обновленное сводное руководство по программному ведению случаев латентной туберкулезной инфекции. Женева: Всемирная организация здравоохранения; 2018 (http://www.who.int/tb/publications/2018/latent-tuberculosis-infection/en/, по состоянию на 31 марта 2021 г.).
· extracted · link · source:references/10665-331525-rus.page-158.40.jsonОбновленное сводное руководство по программному ведению случаев латентной туберкулезной инфекции. Женева: Всемирная организация здравоохранения; 2018 (http://www.who.int/tb/publications/2018/latent-tuberculosis-infection/en/, по состоянию на 31 марта 2021 г.).
- Issued
- 2021
- Type
- document
- As printed
- Обновленное сводное руководство по программному ведению случаев латентной туберкулезной инфекции. Женева: Всемирная организация здравоохранения; 2018 (http://www.who.int/tb/publications/2018/latent-tuberculosis-infection/en/, по состоянию на 31 марта 2021 г.).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.40 - provenance: extracted
- read from
references/10665-331525-rus.page-158.40.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Chest radiography in tuberculosis detection – summary of current WHO recommendations and guidance on programmatic approaches. Geneva: World Health Organization; 2016 (who.int/tb/publications/chest-radiography/en/, accessed 15 March 2020).
· extracted · source:references/10665-331525-rus.page-158.41.jsonChest radiography in tuberculosis detection – summary of current WHO recommendations and guidance on programmatic approaches. Geneva: World Health Organization; 2016 (who.int/tb/publications/chest-radiography/en/, accessed 15 March 2020).
- Issued
- 2016
- Type
- document
- Accessed
- 15 March 2020
- As printed
- Chest radiography in tuberculosis detection – summary of current WHO recommendations and guidance on programmatic approaches. Geneva: World Health Organization; 2016 (who.int/tb/publications/chest-radiography/en/, accessed 15 March 2020).
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.41 - provenance: extracted
- read from
references/10665-331525-rus.page-158.41.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Samandari T, Bishai D, Luteijn M, Mosimaneotsile B, Motsamai O, Postma M, et al. Costs and consequences of additional chest x-ray in a tuberculosis prevention program in Botswana. Am J Respir Crit Care Med. 2011;183(8):1103–11.
· extracted · source:references/10665-331525-rus.page-158.42.jsonSamandari T, Bishai D, Luteijn M, Mosimaneotsile B, Motsamai O, Postma M, et al. Costs and consequences of additional chest x-ray in a tuberculosis prevention program in Botswana. Am J Respir Crit Care Med. 2011;183(8):1103–11.
- Issued
- 2011
- Type
- article-journal
- As printed
- Samandari T, Bishai D, Luteijn M, Mosimaneotsile B, Motsamai O, Postma M, et al. Costs and consequences of additional chest x-ray in a tuberculosis prevention program in Botswana. Am J Respir Crit Care Med. 2011;183(8):1103–11.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.42 - provenance: extracted
- read from
references/10665-331525-rus.page-158.42.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
TB Elimination. Interferon-Gamma Release Assays (IGRAs) – Blood tests for TB infection. Atlanta: Centre for Disease Control and Prevention (https://www.cdc.gov/tb/publications/factsheets/testing/IGRA.pdf, accessed 15 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.43.jsonTB Elimination. Interferon-Gamma Release Assays (IGRAs) – Blood tests for TB infection. Atlanta: Centre for Disease Control and Prevention (https://www.cdc.gov/tb/publications/factsheets/testing/IGRA.pdf, accessed 15 March 2020).
- Type
- document
- Accessed
- 15 March 2020
- As printed
- TB Elimination. Interferon-Gamma Release Assays (IGRAs) – Blood tests for TB infection. Atlanta: Centre for Disease Control and Prevention (https://www.cdc.gov/tb/publications/factsheets/testing/IGRA.pdf, accessed 15 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.43 - provenance: extracted
- read from
references/10665-331525-rus.page-158.43.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;(1) (https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000171.pub3/abstract, accessed 15 March 2020).
· extracted · doi:10.1002/14651858.CD000171.pub3/abstract · source:references/10665-331525-rus.page-158.44.jsonAkolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;(1) (https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000171.pub3/abstract, accessed 15 March 2020).
- Issued
- 2010
- Type
- document
- DOI
- 10.1002/14651858.CD000171.pub3/abstract
- Accessed
- 15 March 2020
- As printed
- Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;(1) (https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000171.pub3/abstract, accessed 15 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.44 - provenance: extracted
- read from
references/10665-331525-rus.page-158.44.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med. 2017;167(4):248–55.
· extracted · source:references/10665-331525-rus.page-158.45.jsonZenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med. 2017;167(4):248–55.
- Issued
- 2017
- Type
- article-journal
- As printed
- Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med. 2017;167(4):248–55.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.45 - provenance: extracted
- read from
references/10665-331525-rus.page-158.45.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Hamada Y, Ford N, Schenkel K, Getahun H. Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review Int J Tuberc Lung Dis 2018;22(12):1422–28.
· extracted · source:references/10665-331525-rus.page-158.46.jsonHamada Y, Ford N, Schenkel K, Getahun H. Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review Int J Tuberc Lung Dis 2018;22(12):1422–28.
- Issued
- 2018
- Type
- article-journal
- As printed
- Hamada Y, Ford N, Schenkel K, Getahun H. Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review Int J Tuberc Lung Dis 2018;22(12):1422–28.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.46 - provenance: extracted
- read from
references/10665-331525-rus.page-158.46.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev 2013;7 (DOI: 10.1002/14651858.CD007545.pub2, accessed 16 March 2020).
· extracted · doi:10.1002/14651858.CD007545.pub2 · source:references/10665-331525-rus.page-158.47.jsonSharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev 2013;7 (DOI: 10.1002/14651858.CD007545.pub2, accessed 16 March 2020).
- Issued
- 2013
- Type
- document
- DOI
- 10.1002/14651858.CD007545.pub2
- Accessed
- 16 March 2020
- As printed
- Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev 2013;7 (DOI: 10.1002/14651858.CD007545.pub2, accessed 16 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.47 - provenance: extracted
- read from
references/10665-331525-rus.page-158.47.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P, et al. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis. 2017;17(1):265.
· extracted · source:references/10665-331525-rus.page-158.48.jsonPease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P, et al. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis. 2017;17(1):265.
- Issued
- 2017
- Type
- article-journal
- As printed
- Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P, et al. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis. 2017;17(1):265.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.48 - provenance: extracted
- read from
references/10665-331525-rus.page-158.48.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Руководство по ведению пациентов с латентной туберкулезной инфекцией. Женева: Всемирная организация здравоохранения; 2015 (https://apps.who.int/medicinedocs/documents/s21682en/s21682en.pdf, по состоянию на 31 марта 2021 г.).
· extracted · link · source:references/10665-331525-rus.page-158.49.jsonРуководство по ведению пациентов с латентной туберкулезной инфекцией. Женева: Всемирная организация здравоохранения; 2015 (https://apps.who.int/medicinedocs/documents/s21682en/s21682en.pdf, по состоянию на 31 марта 2021 г.).
- Issued
- 2021
- Type
- document
- As printed
- Руководство по ведению пациентов с латентной туберкулезной инфекцией. Женева: Всемирная организация здравоохранения; 2015 (https://apps.who.int/medicinedocs/documents/s21682en/s21682en.pdf, по состоянию на 31 марта 2021 г.).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.49 - provenance: extracted
- read from
references/10665-331525-rus.page-158.49.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Behr MA, Edelstein PH, Ramakrishnan L. Revisiting the timetable of tuberculosis. BMJ. 2018;362:k2738.
· extracted · source:references/10665-331525-rus.page-158.5.jsonBehr MA, Edelstein PH, Ramakrishnan L. Revisiting the timetable of tuberculosis. BMJ. 2018;362:k2738.
- Issued
- 2018
- Type
- article-journal
- As printed
- Behr MA, Edelstein PH, Ramakrishnan L. Revisiting the timetable of tuberculosis. BMJ. 2018;362:k2738.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.5 - provenance: extracted
- read from
references/10665-331525-rus.page-158.5.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Guidance for national tuberculosis programmes on the management of tuberculosis in children. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/bitstream/handle/10665/112360/9789241548748_eng.pdf, accessed 16 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.50.jsonGuidance for national tuberculosis programmes on the management of tuberculosis in children. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/bitstream/handle/10665/112360/9789241548748_eng.pdf, accessed 16 March 2020).
- Issued
- 2014
- Type
- document
- Accessed
- 16 March 2020
- As printed
- Guidance for national tuberculosis programmes on the management of tuberculosis in children. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/bitstream/handle/10665/112360/9789241548748_eng.pdf, accessed 16 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.50 - provenance: extracted
- read from
references/10665-331525-rus.page-158.50.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
January 2020. Medicines catalogue. Geneva: Global Drug Facility; 2020 (http://www.stoptb.org/assets/documents/gdf/drugsupply/GDFMedicinesCatalog.pdf, accessed 16 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.51.jsonJanuary 2020. Medicines catalogue. Geneva: Global Drug Facility; 2020 (http://www.stoptb.org/assets/documents/gdf/drugsupply/GDFMedicinesCatalog.pdf, accessed 16 March 2020).
- Issued
- 2020
- Type
- document
- Accessed
- 16 March 2020
- As printed
- January 2020. Medicines catalogue. Geneva: Global Drug Facility; 2020 (http://www.stoptb.org/assets/documents/gdf/drugsupply/GDFMedicinesCatalog.pdf, accessed 16 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.51 - provenance: extracted
- read from
references/10665-331525-rus.page-158.51.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–66.
· extracted · source:references/10665-331525-rus.page-158.52.jsonSterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–66.
- Issued
- 2011
- Type
- article-journal
- As printed
- Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–66.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.52 - provenance: extracted
- read from
references/10665-331525-rus.page-158.52.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS. 2016;30(10):1607–15.
· extracted · source:references/10665-331525-rus.page-158.53.jsonSterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS. 2016;30(10):1607–15.
- Issued
- 2016
- Type
- article-journal
- As printed
- Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS. 2016;30(10):1607–15.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.53 - provenance: extracted
- read from
references/10665-331525-rus.page-158.53.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One month of rifapentine plus isoniazid to prevent hiv-related tuberculosis. N Engl J Med. 2019;380(11):1001–11.
· extracted · source:references/10665-331525-rus.page-158.54.jsonSwindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One month of rifapentine plus isoniazid to prevent hiv-related tuberculosis. N Engl J Med. 2019;380(11):1001–11.
- Issued
- 2019
- Type
- article-journal
- As printed
- Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One month of rifapentine plus isoniazid to prevent hiv-related tuberculosis. N Engl J Med. 2019;380(11):1001–11.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.54 - provenance: extracted
- read from
references/10665-331525-rus.page-158.54.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Landmark deal secures significant discount on price of medicine to prevent TB. Press realease 2019. Unitaid [веб-сайт] (https://unitaid.org/news-blog/landmark-deal-secures-significant-discount-on-price-of-medicine- to-prevent-tb/#en, accessed 16 March 2020.
· extracted · link · source:references/10665-331525-rus.page-158.55.jsonLandmark deal secures significant discount on price of medicine to prevent TB. Press realease 2019. Unitaid [веб-сайт] (https://unitaid.org/news-blog/landmark-deal-secures-significant-discount-on-price-of-medicine- to-prevent-tb/#en, accessed 16 March 2020.
- Issued
- 2019
- Type
- document
- Accessed
- 16 March 2020
- As printed
- Landmark deal secures significant discount on price of medicine to prevent TB. Press realease 2019. Unitaid [веб-сайт] (https://unitaid.org/news-blog/landmark-deal-secures-significant-discount-on-price-of-medicine- to-prevent-tb/#en, accessed 16 March 2020.
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.55 - provenance: extracted
- read from
references/10665-331525-rus.page-158.55.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Salgame P, Geadas C, Collins L, Jones-López E, Ellner JJ. Latent tuberculosis infection Revisiting and revising concepts. Tuberculosis. 2015;95(4):373–84.
· extracted · source:references/10665-331525-rus.page-158.56.jsonSalgame P, Geadas C, Collins L, Jones-López E, Ellner JJ. Latent tuberculosis infection Revisiting and revising concepts. Tuberculosis. 2015;95(4):373–84.
- Issued
- 2015
- Type
- article-journal
- As printed
- Salgame P, Geadas C, Collins L, Jones-López E, Ellner JJ. Latent tuberculosis infection Revisiting and revising concepts. Tuberculosis. 2015;95(4):373–84.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.56 - provenance: extracted
- read from
references/10665-331525-rus.page-158.56.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Catalyzing pediatric tuberculosis innovations (CaP TB): Short-course treatment regimens to prevent TB: 3HP and 3RH. Technical Brief. IMPAACT4TB [веб-сайт], 2019 (https://www.impaact4tb.org/catalyzing-pediatric-tuberculosis-innovations-cap-tb-short-course-treatment-regimens-to-prevent-tb-3hp-and-3rh/, accessed 16 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.57.jsonCatalyzing pediatric tuberculosis innovations (CaP TB): Short-course treatment regimens to prevent TB: 3HP and 3RH. Technical Brief. IMPAACT4TB [веб-сайт], 2019 (https://www.impaact4tb.org/catalyzing-pediatric-tuberculosis-innovations-cap-tb-short-course-treatment-regimens-to-prevent-tb-3hp-and-3rh/, accessed 16 March 2020).
- Issued
- 2019
- Type
- document
- Accessed
- 16 March 2020
- As printed
- Catalyzing pediatric tuberculosis innovations (CaP TB): Short-course treatment regimens to prevent TB: 3HP and 3RH. Technical Brief. IMPAACT4TB [веб-сайт], 2019 (https://www.impaact4tb.org/catalyzing-pediatric-tuberculosis-innovations-cap-tb-short-course-treatment-regimens-to-prevent-tb-3hp-and-3rh/, accessed 16 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.57 - provenance: extracted
- read from
references/10665-331525-rus.page-158.57.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
TPT implementation tools. IMPAACT4TB [веб-сайт], 2019 (https://www.impaact4tb.org/3hp-documents/, по состоянию на 31 марта 2021 г.).
· extracted · link · source:references/10665-331525-rus.page-158.58.jsonTPT implementation tools. IMPAACT4TB [веб-сайт], 2019 (https://www.impaact4tb.org/3hp-documents/, по состоянию на 31 марта 2021 г.).
- Issued
- 2021
- Type
- document
- As printed
- TPT implementation tools. IMPAACT4TB [веб-сайт], 2019 (https://www.impaact4tb.org/3hp-documents/, по состоянию на 31 марта 2021 г.).
Sources
- www.impaact4tb.org/3hp-documents/ (canonical)
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.58 - provenance: extracted
- read from
references/10665-331525-rus.page-158.58.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Snider DE. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980;61(4):191–6.
· extracted · source:references/10665-331525-rus.page-158.59.jsonSnider DE. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980;61(4):191–6.
- Issued
- 1980
- Type
- article-journal
- As printed
- Snider DE. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980;61(4):191–6.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.59 - provenance: extracted
- read from
references/10665-331525-rus.page-158.59.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Borgdorff MW, Sebek M, Geskus RB, Kremer K, Kalisvaart N, van Soolingen D. The incubation period distribution of tuberculosis estimated with a molecular epidemiological approach. Int J Epidemiol. 2011;40(4):964–70.
· extracted · source:references/10665-331525-rus.page-158.6.jsonBorgdorff MW, Sebek M, Geskus RB, Kremer K, Kalisvaart N, van Soolingen D. The incubation period distribution of tuberculosis estimated with a molecular epidemiological approach. Int J Epidemiol. 2011;40(4):964–70.
- Issued
- 2011
- Type
- article-journal
- As printed
- Borgdorff MW, Sebek M, Geskus RB, Kremer K, Kalisvaart N, van Soolingen D. The incubation period distribution of tuberculosis estimated with a molecular epidemiological approach. Int J Epidemiol. 2011;40(4):964–70.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.6 - provenance: extracted
- read from
references/10665-331525-rus.page-158.6.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Biehl JP, Nimitz HJ. Studies on the use of a high dose of isoniazid. I. Toxicity studies. Am Rev Tuberc. 1954;70(3):430–41.
· extracted · source:references/10665-331525-rus.page-158.60.jsonBiehl JP, Nimitz HJ. Studies on the use of a high dose of isoniazid. I. Toxicity studies. Am Rev Tuberc. 1954;70(3):430–41.
- Issued
- 1954
- Type
- article-journal
- As printed
- Biehl JP, Nimitz HJ. Studies on the use of a high dose of isoniazid. I. Toxicity studies. Am Rev Tuberc. 1954;70(3):430–41.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.60 - provenance: extracted
- read from
references/10665-331525-rus.page-158.60.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Oestreicher R, Dressler SH, Middlebrook G. Peripheral neuritis in tuberculous patients treated with isoniazid. Am Rev Tuberc. 1954;70(3):504–8.
· extracted · source:references/10665-331525-rus.page-158.61.jsonOestreicher R, Dressler SH, Middlebrook G. Peripheral neuritis in tuberculous patients treated with isoniazid. Am Rev Tuberc. 1954;70(3):504–8.
- Issued
- 1954
- Type
- article-journal
- As printed
- Oestreicher R, Dressler SH, Middlebrook G. Peripheral neuritis in tuberculous patients treated with isoniazid. Am Rev Tuberc. 1954;70(3):504–8.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.61 - provenance: extracted
- read from
references/10665-331525-rus.page-158.61.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Denholm JT, McBryde ES, Eisen DP, Penington JS, Chen C, Street AC. Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study. Drug Healthc Patient Saf. 2014;6:145–9.
· extracted · source:references/10665-331525-rus.page-158.62.jsonDenholm JT, McBryde ES, Eisen DP, Penington JS, Chen C, Street AC. Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study. Drug Healthc Patient Saf. 2014;6:145–9.
- Issued
- 2014
- Type
- article-journal
- As printed
- Denholm JT, McBryde ES, Eisen DP, Penington JS, Chen C, Street AC. Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study. Drug Healthc Patient Saf. 2014;6:145–9.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.62 - provenance: extracted
- read from
references/10665-331525-rus.page-158.62.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Money GL. Isoniazid neuropathies in malnourished tuberculous patients. J Trop Med Hyg. 1959;62(8):198–202.
· extracted · source:references/10665-331525-rus.page-158.63.jsonMoney GL. Isoniazid neuropathies in malnourished tuberculous patients. J Trop Med Hyg. 1959;62(8):198–202.
- Issued
- 1959
- Type
- article-journal
- As printed
- Money GL. Isoniazid neuropathies in malnourished tuberculous patients. J Trop Med Hyg. 1959;62(8):198–202.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.63 - provenance: extracted
- read from
references/10665-331525-rus.page-158.63.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Toman K, Frieden TR. Toman’s tuberculosis: case detection, treatment and monitoring; questions and answers. 2nd edition. Geneva: World Health Organization; 2004.
· extracted · source:references/10665-331525-rus.page-158.64.jsonToman K, Frieden TR. Toman’s tuberculosis: case detection, treatment and monitoring; questions and answers. 2nd edition. Geneva: World Health Organization; 2004.
- Issued
- 2004
- Type
- document
- As printed
- Toman K, Frieden TR. Toman’s tuberculosis: case detection, treatment and monitoring; questions and answers. 2nd edition. Geneva: World Health Organization; 2004.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.64 - provenance: extracted
- read from
references/10665-331525-rus.page-158.64.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
McCune R, Deuschle K, Mcdermott W. The delayed appearance of isoniazid antagonism by pyridoxine in vivo. Am Rev Tuberc Pulm Dis. 1957;76(6):1100–5.
· extracted · source:references/10665-331525-rus.page-158.65.jsonMcCune R, Deuschle K, Mcdermott W. The delayed appearance of isoniazid antagonism by pyridoxine in vivo. Am Rev Tuberc Pulm Dis. 1957;76(6):1100–5.
- Issued
- 1957
- Type
- article-journal
- As printed
- McCune R, Deuschle K, Mcdermott W. The delayed appearance of isoniazid antagonism by pyridoxine in vivo. Am Rev Tuberc Pulm Dis. 1957;76(6):1100–5.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.65 - provenance: extracted
- read from
references/10665-331525-rus.page-158.65.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, et al. Sensory neuropathy from pyridoxine abuse. N Engl J Med. 1983;309(8):445–8.
· extracted · source:references/10665-331525-rus.page-158.66.jsonSchaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, et al. Sensory neuropathy from pyridoxine abuse. N Engl J Med. 1983;309(8):445–8.
- Issued
- 1983
- Type
- article-journal
- As printed
- Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, et al. Sensory neuropathy from pyridoxine abuse. N Engl J Med. 1983;309(8):445–8.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.66 - provenance: extracted
- read from
references/10665-331525-rus.page-158.66.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Ghavanini AA, Kimpinski K. Revisiting the evidence for neuropathy caused by pyridoxine deficiency and excess. J Clin Neuromuscul Dis. 2014;16(1):25–31.
· extracted · source:references/10665-331525-rus.page-158.67.jsonGhavanini AA, Kimpinski K. Revisiting the evidence for neuropathy caused by pyridoxine deficiency and excess. J Clin Neuromuscul Dis. 2014;16(1):25–31.
- Issued
- 2014
- Type
- article-journal
- As printed
- Ghavanini AA, Kimpinski K. Revisiting the evidence for neuropathy caused by pyridoxine deficiency and excess. J Clin Neuromuscul Dis. 2014;16(1):25–31.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.67 - provenance: extracted
- read from
references/10665-331525-rus.page-158.67.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Sotgiu G, Matteelli A, Getahun H, Girardi E, Schepisi MS, Centis R, et al. Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion. Eur Respir J. 2015;45(4):1170–3.
· extracted · source:references/10665-331525-rus.page-158.68.jsonSotgiu G, Matteelli A, Getahun H, Girardi E, Schepisi MS, Centis R, et al. Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion. Eur Respir J. 2015;45(4):1170–3.
- Issued
- 2015
- Type
- article-journal
- As printed
- Sotgiu G, Matteelli A, Getahun H, Girardi E, Schepisi MS, Centis R, et al. Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion. Eur Respir J. 2015;45(4):1170–3.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.68 - provenance: extracted
- read from
references/10665-331525-rus.page-158.68.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ. 1982;60(4):555–64.
· extracted · source:references/10665-331525-rus.page-158.69.jsonInternational Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ. 1982;60(4):555–64.
- Issued
- 1982
- Type
- article-journal
- As printed
- International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ. 1982;60(4):555–64.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.69 - provenance: extracted
- read from
references/10665-331525-rus.page-158.69.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Стратегия ВОЗ по ликвидации туберкулеза. Всемирная организация здравоохранения [веб-сайт] (http://www.who.int/tb/strategy/en/ по состоянию на 31 марта 2021 г.).
· extracted · link · source:references/10665-331525-rus.page-158.7.jsonСтратегия ВОЗ по ликвидации туберкулеза. Всемирная организация здравоохранения [веб-сайт] (http://www.who.int/tb/strategy/en/ по состоянию на 31 марта 2021 г.).
- Issued
- 2021
- Type
- document
- As printed
- Стратегия ВОЗ по ликвидации туберкулеза. Всемирная организация здравоохранения [веб-сайт] (http://www.who.int/tb/strategy/en/ по состоянию на 31 марта 2021 г.).
Sources
- www.who.int/tb/strategy/en/ (canonical)
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.7 - provenance: extracted
- read from
references/10665-331525-rus.page-158.7.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Comstock GW, Ferebee SH. How much isoniazid is needed for prophylaxis? Am Rev Respir Dis. 1970;101(5):780–2.
· extracted · source:references/10665-331525-rus.page-158.70.jsonComstock GW, Ferebee SH. How much isoniazid is needed for prophylaxis? Am Rev Respir Dis. 1970;101(5):780–2.
- Issued
- 1970
- Type
- article-journal
- As printed
- Comstock GW, Ferebee SH. How much isoniazid is needed for prophylaxis? Am Rev Respir Dis. 1970;101(5):780–2.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.70 - provenance: extracted
- read from
references/10665-331525-rus.page-158.70.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440–53.
· extracted · source:references/10665-331525-rus.page-158.71.jsonMenzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440–53.
- Issued
- 2018
- Type
- article-journal
- As printed
- Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440–53.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.71 - provenance: extracted
- read from
references/10665-331525-rus.page-158.71.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Sandul AL, Nwana N, Holcombe JM, Lobato MN, Marks S, Webb R, et al. High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent mycobacterium tuberculosis infection. Clin Infect Dis. 2017;65(7):1085–93.
· extracted · source:references/10665-331525-rus.page-158.72.jsonSandul AL, Nwana N, Holcombe JM, Lobato MN, Marks S, Webb R, et al. High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent mycobacterium tuberculosis infection. Clin Infect Dis. 2017;65(7):1085–93.
- Issued
- 2017
- Type
- article-journal
- As printed
- Sandul AL, Nwana N, Holcombe JM, Lobato MN, Marks S, Webb R, et al. High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent mycobacterium tuberculosis infection. Clin Infect Dis. 2017;65(7):1085–93.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.72 - provenance: extracted
- read from
references/10665-331525-rus.page-158.72.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46(6):1563–76.
· extracted · source:references/10665-331525-rus.page-158.73.jsonGetahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46(6):1563–76.
- Issued
- 2015
- Type
- article-journal
- As printed
- Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46(6):1563–76.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.73 - provenance: extracted
- read from
references/10665-331525-rus.page-158.73.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Guidelines for the treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva: World Health Organization; 2017 (http://apps.who.int/iris/bitstream/10665/255052/1/9789241550000-eng.pdf, accessed 18 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.74.jsonGuidelines for the treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva: World Health Organization; 2017 (http://apps.who.int/iris/bitstream/10665/255052/1/9789241550000-eng.pdf, accessed 18 March 2020).
- Issued
- 2017
- Type
- document
- Accessed
- 18 March 2020
- As printed
- Guidelines for the treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva: World Health Organization; 2017 (http://apps.who.int/iris/bitstream/10665/255052/1/9789241550000-eng.pdf, accessed 18 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.74 - provenance: extracted
- read from
references/10665-331525-rus.page-158.74.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Leveraging differentiated ART delivery models for stable clients to scale up TB preventive therapy. Differentiated Service Delivery [Supplement]. Geneva: International AIDS Society (https://differentiatedservicedelivery.org/Portals/0/adam/Content/3qTmUzah5kWCdeEogdiJ5A/File/IAS%20TPT%20supplement%208-Pager%20DIGITAL.pdf, accessed 18 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.75.jsonLeveraging differentiated ART delivery models for stable clients to scale up TB preventive therapy. Differentiated Service Delivery [Supplement]. Geneva: International AIDS Society (https://differentiatedservicedelivery.org/Portals/0/adam/Content/3qTmUzah5kWCdeEogdiJ5A/File/IAS%20TPT%20supplement%208-Pager%20DIGITAL.pdf, accessed 18 March 2020).
- Type
- document
- Accessed
- 18 March 2020
- As printed
- Leveraging differentiated ART delivery models for stable clients to scale up TB preventive therapy. Differentiated Service Delivery [Supplement]. Geneva: International AIDS Society (https://differentiatedservicedelivery.org/Portals/0/adam/Content/3qTmUzah5kWCdeEogdiJ5A/File/IAS%20TPT%20supplement%208-Pager%20DIGITAL.pdf, accessed 18 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.75 - provenance: extracted
- read from
references/10665-331525-rus.page-158.75.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Differentiated models of delivering HIV care: Perspectives from people living with HIV and health care workers in 7 African countries. ICAP HIV learning network_the CQUIN project for differentaited service delivery [веб-сайт] (https://cquin.icap.columbia.edu/resources/issue-brief-differentiated-models-of-delivering-hiv-care//, accessed 18 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.76.jsonDifferentiated models of delivering HIV care: Perspectives from people living with HIV and health care workers in 7 African countries. ICAP HIV learning network_the CQUIN project for differentaited service delivery [веб-сайт] (https://cquin.icap.columbia.edu/resources/issue-brief-differentiated-models-of-delivering-hiv-care//, accessed 18 March 2020).
- Type
- document
- Accessed
- 18 March 2020
- As printed
- Differentiated models of delivering HIV care: Perspectives from people living with HIV and health care workers in 7 African countries. ICAP HIV learning network_the CQUIN project for differentaited service delivery [веб-сайт] (https://cquin.icap.columbia.edu/resources/issue-brief-differentiated-models-of-delivering-hiv-care//, accessed 18 March 2020).
Sources
- cquin.icap.columbia.edu/resources/issue-brief-differentiated-models-of-delivering-hiv-care// (canonical)
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.76 - provenance: extracted
- read from
references/10665-331525-rus.page-158.76.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Gupta A, Nayak U, Ram M, Bhosale R, Patil S, Basavraj A, et al. Postpartum tuberculosis incidence and mortality among HIV-Infected women and their infants in Pune, India, 2002–2005. Clin Infect Dis. 2007;45(2):241–9.
· extracted · source:references/10665-331525-rus.page-158.77.jsonGupta A, Nayak U, Ram M, Bhosale R, Patil S, Basavraj A, et al. Postpartum tuberculosis incidence and mortality among HIV-Infected women and their infants in Pune, India, 2002–2005. Clin Infect Dis. 2007;45(2):241–9.
- Issued
- 2007
- Type
- article-journal
- As printed
- Gupta A, Nayak U, Ram M, Bhosale R, Patil S, Basavraj A, et al. Postpartum tuberculosis incidence and mortality among HIV-Infected women and their infants in Pune, India, 2002–2005. Clin Infect Dis. 2007;45(2):241–9.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.77 - provenance: extracted
- read from
references/10665-331525-rus.page-158.77.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Salazar-Austin N, Hoffmann J, Cohn S, Mashabela F, Waja Z, Lala S, et al. Poor obstetric and infant outcomes in human immunodeficiency virus-infected pregnant women with tuberculosis in South Africa: The Tshepiso Study. Clin Infect Dis. 2018;66(6):921–9.
· extracted · source:references/10665-331525-rus.page-158.78.jsonSalazar-Austin N, Hoffmann J, Cohn S, Mashabela F, Waja Z, Lala S, et al. Poor obstetric and infant outcomes in human immunodeficiency virus-infected pregnant women with tuberculosis in South Africa: The Tshepiso Study. Clin Infect Dis. 2018;66(6):921–9.
- Issued
- 2018
- Type
- article-journal
- As printed
- Salazar-Austin N, Hoffmann J, Cohn S, Mashabela F, Waja Z, Lala S, et al. Poor obstetric and infant outcomes in human immunodeficiency virus-infected pregnant women with tuberculosis in South Africa: The Tshepiso Study. Clin Infect Dis. 2018;66(6):921–9.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.78 - provenance: extracted
- read from
references/10665-331525-rus.page-158.78.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Isoniazid tablet, USP. Maryland: U.S. Food and Drug Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008678s028lbl.pdf, accessed 18 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.79.jsonIsoniazid tablet, USP. Maryland: U.S. Food and Drug Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008678s028lbl.pdf, accessed 18 March 2020).
- Issued
- 2016
- Type
- document
- Accessed
- 18 March 2020
- As printed
- Isoniazid tablet, USP. Maryland: U.S. Food and Drug Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008678s028lbl.pdf, accessed 18 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.79 - provenance: extracted
- read from
references/10665-331525-rus.page-158.79.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Стратегия ВОЗ по ликвидации туберкулеза. Всемирная организация здравоохранения [веб-сайт]; 2013 (https://www.who.int/tb/post2015_strategy/en/ по состоянию на 31 марта 2021 г.).
· extracted · link · source:references/10665-331525-rus.page-158.8.jsonСтратегия ВОЗ по ликвидации туберкулеза. Всемирная организация здравоохранения [веб-сайт]; 2013 (https://www.who.int/tb/post2015_strategy/en/ по состоянию на 31 марта 2021 г.).
- Issued
- 2021
- Type
- document
- As printed
- Стратегия ВОЗ по ликвидации туберкулеза. Всемирная организация здравоохранения [веб-сайт]; 2013 (https://www.who.int/tb/post2015_strategy/en/ по состоянию на 31 марта 2021 г.).
Sources
- www.who.int/tb/post2015_strategy/en/ (canonical)
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.8 - provenance: extracted
- read from
references/10665-331525-rus.page-158.8.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Rifadin® (rifampin capsules USP) and Rifadin® IV (rifampin for injection USP). Maryland: U.S. Food and Drug Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050420s073,050627s012lbl.pdf, accessed 18 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.80.jsonRifadin® (rifampin capsules USP) and Rifadin® IV (rifampin for injection USP). Maryland: U.S. Food and Drug Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050420s073,050627s012lbl.pdf, accessed 18 March 2020).
- Issued
- 2016
- Type
- document
- Accessed
- 18 March 2020
- As printed
- Rifadin® (rifampin capsules USP) and Rifadin® IV (rifampin for injection USP). Maryland: U.S. Food and Drug Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050420s073,050627s012lbl.pdf, accessed 18 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.80 - provenance: extracted
- read from
references/10665-331525-rus.page-158.80.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, et al. Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med. 2019;381(14):1333–46.
· extracted · source:references/10665-331525-rus.page-158.81.jsonGupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, et al. Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med. 2019;381(14):1333–46.
- Issued
- 2019
- Type
- article-journal
- As printed
- Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, et al. Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med. 2019;381(14):1333–46.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.81 - provenance: extracted
- read from
references/10665-331525-rus.page-158.81.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Msandiwa R, et al. Population pharmacokinetics of rifampin in pregnant women with tuberculosis and HIV coinfection in Soweto, South Africa. Antimicrob Agents Chemother. 2015;60(3):1234–41.
· extracted · source:references/10665-331525-rus.page-158.82.jsonDenti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Msandiwa R, et al. Population pharmacokinetics of rifampin in pregnant women with tuberculosis and HIV coinfection in Soweto, South Africa. Antimicrob Agents Chemother. 2015;60(3):1234–41.
- Issued
- 2015
- Type
- article-journal
- As printed
- Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Msandiwa R, et al. Population pharmacokinetics of rifampin in pregnant women with tuberculosis and HIV coinfection in Soweto, South Africa. Antimicrob Agents Chemother. 2015;60(3):1234–41.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.82 - provenance: extracted
- read from
references/10665-331525-rus.page-158.82.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Partosch F, Mielke H, Stahlmann R, Gundert-Remy U. Exposure of nursed infants to maternal treatment with ethambutol and rifampicin. Basic Clin Pharmacol Toxicol. 2018;123(2):213–20.
· extracted · source:references/10665-331525-rus.page-158.83.jsonPartosch F, Mielke H, Stahlmann R, Gundert-Remy U. Exposure of nursed infants to maternal treatment with ethambutol and rifampicin. Basic Clin Pharmacol Toxicol. 2018;123(2):213–20.
- Issued
- 2018
- Type
- article-journal
- As printed
- Partosch F, Mielke H, Stahlmann R, Gundert-Remy U. Exposure of nursed infants to maternal treatment with ethambutol and rifampicin. Basic Clin Pharmacol Toxicol. 2018;123(2):213–20.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.83 - provenance: extracted
- read from
references/10665-331525-rus.page-158.83.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Mngqibisa R, Kendall MA, Dooley K, Wu X, Firnhaber C, McIlleron H, et al. Pharmacokinetics and pharmacodynamics of depot medroxyprogesterone acetate (DMPA) in African women receiving treatment for HIV and TB: Potential concern for standard dosing frequency. Clin Infect Dis 2019; ciz863. doi: 10.1093/cid/ciz863, accessed 18 March 2020).
· extracted · doi:10.1093/cid/ciz863 · source:references/10665-331525-rus.page-158.84.jsonMngqibisa R, Kendall MA, Dooley K, Wu X, Firnhaber C, McIlleron H, et al. Pharmacokinetics and pharmacodynamics of depot medroxyprogesterone acetate (DMPA) in African women receiving treatment for HIV and TB: Potential concern for standard dosing frequency. Clin Infect Dis 2019; ciz863. doi: 10.1093/cid/ciz863, accessed 18 March 2020).
- Issued
- 2019
- Type
- document
- DOI
- 10.1093/cid/ciz863
- Accessed
- 18 March 2020
- As printed
- Mngqibisa R, Kendall MA, Dooley K, Wu X, Firnhaber C, McIlleron H, et al. Pharmacokinetics and pharmacodynamics of depot medroxyprogesterone acetate (DMPA) in African women receiving treatment for HIV and TB: Potential concern for standard dosing frequency. Clin Infect Dis 2019; ciz863. doi: 10.1093/cid/ciz863, accessed 18 March 2020).
Sources
- doi:10.1093/cid/ciz863 (doi)
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.84 - provenance: extracted
- read from
references/10665-331525-rus.page-158.84.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Sadaphal P, Astemborski J, Graham NMH, Sheely L, Bonds M, Madison A, et al. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis. 2001;33(10):1687–91.
· extracted · source:references/10665-331525-rus.page-158.85.jsonSadaphal P, Astemborski J, Graham NMH, Sheely L, Bonds M, Madison A, et al. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis. 2001;33(10):1687–91.
- Issued
- 2001
- Type
- article-journal
- As printed
- Sadaphal P, Astemborski J, Graham NMH, Sheely L, Bonds M, Madison A, et al. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis. 2001;33(10):1687–91.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.85 - provenance: extracted
- read from
references/10665-331525-rus.page-158.85.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B: AIDS. 2007;21(10):1301–8.
· extracted · source:references/10665-331525-rus.page-158.86.jsonHoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B: AIDS. 2007;21(10):1301–8.
- Issued
- 2007
- Type
- article-journal
- As printed
- Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B: AIDS. 2007;21(10):1301–8.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.86 - provenance: extracted
- read from
references/10665-331525-rus.page-158.86.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
McIlleron H, Denti P, Cohn S, Mashabela F, Hoffmann JD, Shembe S, et al. Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants. J Antimicrob Chemother. 2017;72(7):2028–34.
· extracted · source:references/10665-331525-rus.page-158.87.jsonMcIlleron H, Denti P, Cohn S, Mashabela F, Hoffmann JD, Shembe S, et al. Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants. J Antimicrob Chemother. 2017;72(7):2028–34.
- Issued
- 2017
- Type
- article-journal
- As printed
- McIlleron H, Denti P, Cohn S, Mashabela F, Hoffmann JD, Shembe S, et al. Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants. J Antimicrob Chemother. 2017;72(7):2028–34.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.87 - provenance: extracted
- read from
references/10665-331525-rus.page-158.87.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Becerra MC, Huang C-C, Lecca L, Bayona J, Contreras C, Calderon R, et al. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. BMJ. 2019;367:l5894.
· extracted · source:references/10665-331525-rus.page-158.88.jsonBecerra MC, Huang C-C, Lecca L, Bayona J, Contreras C, Calderon R, et al. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. BMJ. 2019;367:l5894.
- Issued
- 2019
- Type
- article-journal
- As printed
- Becerra MC, Huang C-C, Lecca L, Bayona J, Contreras C, Calderon R, et al. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. BMJ. 2019;367:l5894.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.88 - provenance: extracted
- read from
references/10665-331525-rus.page-158.88.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Marks SM, Mase SR, Morris SB. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis. Clin Infect Dis. 2017;64(12):1670–7.
· extracted · source:references/10665-331525-rus.page-158.89.jsonMarks SM, Mase SR, Morris SB. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis. Clin Infect Dis. 2017;64(12):1670–7.
- Issued
- 2017
- Type
- article-journal
- As printed
- Marks SM, Mase SR, Morris SB. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis. Clin Infect Dis. 2017;64(12):1670–7.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.89 - provenance: extracted
- read from
references/10665-331525-rus.page-158.89.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Framework towards tuberculosis elimination in low-Incidence countries. Geneva: World Health Organization; 2014 (http://www.ncbi.nlm.nih.gov/books/NBK254256/, accessed 15 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.9.jsonFramework towards tuberculosis elimination in low-Incidence countries. Geneva: World Health Organization; 2014 (http://www.ncbi.nlm.nih.gov/books/NBK254256/, accessed 15 March 2020).
- Issued
- 2014
- Type
- document
- Accessed
- 15 March 2020
- As printed
- Framework towards tuberculosis elimination in low-Incidence countries. Geneva: World Health Organization; 2014 (http://www.ncbi.nlm.nih.gov/books/NBK254256/, accessed 15 March 2020).
Sources
- www.ncbi.nlm.nih.gov/books/NBK254256/ (canonical)
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.9 - provenance: extracted
- read from
references/10665-331525-rus.page-158.9.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Ahmed A, Lutchman GA, Kwo PY. Drug–drug interactions in hepatitis C virus treatment: Do they really matter? Clin Liver Dis. 2017;10(5):111–5.
· extracted · source:references/10665-331525-rus.page-158.90.jsonAhmed A, Lutchman GA, Kwo PY. Drug–drug interactions in hepatitis C virus treatment: Do they really matter? Clin Liver Dis. 2017;10(5):111–5.
- Issued
- 2017
- Type
- article-journal
- As printed
- Ahmed A, Lutchman GA, Kwo PY. Drug–drug interactions in hepatitis C virus treatment: Do they really matter? Clin Liver Dis. 2017;10(5):111–5.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.90 - provenance: extracted
- read from
references/10665-331525-rus.page-158.90.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Kempker RR, Alghamdi WA, Al-Shaer MH, Burch G, Peloquin CA. A pharmacology perspective of simultaneous tuberculosis and hepatitis C treatment. Antimicrob Agents Chemother. 2019 Oct 7; AAC.01215–19. doi: 10.1128/AAC.01215–19, accessed 18 March 2020).
· extracted · doi:10.1128/AAC.01215–19 · source:references/10665-331525-rus.page-158.91.jsonKempker RR, Alghamdi WA, Al-Shaer MH, Burch G, Peloquin CA. A pharmacology perspective of simultaneous tuberculosis and hepatitis C treatment. Antimicrob Agents Chemother. 2019 Oct 7; AAC.01215–19. doi: 10.1128/AAC.01215–19, accessed 18 March 2020).
- Issued
- 2019
- Type
- document
- DOI
- 10.1128/AAC.01215–19
- Accessed
- 18 March 2020
- As printed
- Kempker RR, Alghamdi WA, Al-Shaer MH, Burch G, Peloquin CA. A pharmacology perspective of simultaneous tuberculosis and hepatitis C treatment. Antimicrob Agents Chemother. 2019 Oct 7; AAC.01215–19. doi: 10.1128/AAC.01215–19, accessed 18 March 2020).
Sources
- doi:10.1128/AAC.01215–19 (doi)
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.91 - provenance: extracted
- read from
references/10665-331525-rus.page-158.91.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Friedland G. Infectious disease co-morbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis. J Acquir Immune Defic Syndr 2010;55(Suppl1):S37–42.
· extracted · source:references/10665-331525-rus.page-158.92.jsonFriedland G. Infectious disease co-morbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis. J Acquir Immune Defic Syndr 2010;55(Suppl1):S37–42.
- Issued
- 2010
- Type
- article-journal
- As printed
- Friedland G. Infectious disease co-morbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis. J Acquir Immune Defic Syndr 2010;55(Suppl1):S37–42.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.92 - provenance: extracted
- read from
references/10665-331525-rus.page-158.92.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug Alcohol Depend. 2011;118(2–3):326–34.
· extracted · source:references/10665-331525-rus.page-158.93.jsonMcCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug Alcohol Depend. 2011;118(2–3):326–34.
- Issued
- 2011
- Type
- document
- As printed
- McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug Alcohol Depend. 2011;118(2–3):326–34.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.93 - provenance: extracted
- read from
references/10665-331525-rus.page-158.93.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit drug use: review and update. Clin Infect Dis. 2009;48(1):72–82.
· extracted · source:references/10665-331525-rus.page-158.94.jsonDeiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit drug use: review and update. Clin Infect Dis. 2009;48(1):72–82.
- Issued
- 2009
- Type
- article-journal
- As printed
- Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit drug use: review and update. Clin Infect Dis. 2009;48(1):72–82.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.94 - provenance: extracted
- read from
references/10665-331525-rus.page-158.94.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Mike F. An activist’s guide to rifapentine for the treatment of TB infection. New York: Treatment Action Group; 2019 (https://www.treatmentactiongroup.org/publication/an-activists-guide-to-rifapentine-for-the-treatment-of-tb-infection//, accessed 18 March 2020).
· extracted · link · source:references/10665-331525-rus.page-158.95.jsonMike F. An activist’s guide to rifapentine for the treatment of TB infection. New York: Treatment Action Group; 2019 (https://www.treatmentactiongroup.org/publication/an-activists-guide-to-rifapentine-for-the-treatment-of-tb-infection//, accessed 18 March 2020).
- Issued
- 2019
- Type
- document
- Accessed
- 18 March 2020
- As printed
- Mike F. An activist’s guide to rifapentine for the treatment of TB infection. New York: Treatment Action Group; 2019 (https://www.treatmentactiongroup.org/publication/an-activists-guide-to-rifapentine-for-the-treatment-of-tb-infection//, accessed 18 March 2020).
Sources
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.95 - provenance: extracted
- read from
references/10665-331525-rus.page-158.95.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Aquinas SM, Allan WGL, Horsfall PAL, Jenkins PK, Hung-Yan W, Girling D, et al. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. Br Med J. 1972;1(5803):765–71.
· extracted · source:references/10665-331525-rus.page-158.96.jsonAquinas SM, Allan WGL, Horsfall PAL, Jenkins PK, Hung-Yan W, Girling D, et al. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. Br Med J. 1972;1(5803):765–71.
- Issued
- 1972
- Type
- article-journal
- As printed
- Aquinas SM, Allan WGL, Horsfall PAL, Jenkins PK, Hung-Yan W, Girling D, et al. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. Br Med J. 1972;1(5803):765–71.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.96 - provenance: extracted
- read from
references/10665-331525-rus.page-158.96.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis. 1983;5(Suppl 3):S440–6.
· extracted · source:references/10665-331525-rus.page-158.97.jsonGrosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis. 1983;5(Suppl 3):S440–6.
- Issued
- 1983
- Type
- document
- As printed
- Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis. 1983;5(Suppl 3):S440–6.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.97 - provenance: extracted
- read from
references/10665-331525-rus.page-158.97.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Weiner M, Savic RM, Kenzie WRM, Wing D, Peloquin CA, Engle M, et al. Rifapentine Pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection. J Pediatr Infect Dis Soc. 2014;3(2):132–45.
· extracted · source:references/10665-331525-rus.page-158.98.jsonWeiner M, Savic RM, Kenzie WRM, Wing D, Peloquin CA, Engle M, et al. Rifapentine Pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection. J Pediatr Infect Dis Soc. 2014;3(2):132–45.
- Issued
- 2014
- Type
- article-journal
- As printed
- Weiner M, Savic RM, Kenzie WRM, Wing D, Peloquin CA, Engle M, et al. Rifapentine Pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection. J Pediatr Infect Dis Soc. 2014;3(2):132–45.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.98 - provenance: extracted
- read from
references/10665-331525-rus.page-158.98.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
Sterling TR, Moro RN, Borisov AS, Phillips E, Shepherd G, Adkinson NF, et al. Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT Tuberculosis Study. Clin Infect Dis. 2015;61(4):527–35.
· extracted · source:references/10665-331525-rus.page-158.99.jsonSterling TR, Moro RN, Borisov AS, Phillips E, Shepherd G, Adkinson NF, et al. Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT Tuberculosis Study. Clin Infect Dis. 2015;61(4):527–35.
- Issued
- 2015
- Type
- article-journal
- As printed
- Sterling TR, Moro RN, Borisov AS, Phillips E, Shepherd G, Adkinson NF, et al. Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT Tuberculosis Study. Clin Infect Dis. 2015;61(4):527–35.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-331525-rus.page-158.99 - provenance: extracted
- read from
references/10665-331525-rus.page-158.99.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-331525-rus/sections/page-158.md
-
WHO. WHO operational handbook on tuberculosis: module 1: prevention: tuberculosis preventive treatment.
10665-331525-rus· library · source:library/10665-331525-rus/manifest.jsonld· held:library/10665-331525-rus
export: BibTeX · RIS · CSL-JSON · DC XML